MMP-12, Secreted by Pro-Inflammatory Macrophages, Targets Endoglin in Human Macrophages and Endothelial Cells
Overview
Chemistry
Molecular Biology
Authors
Affiliations
Upon inflammation, monocyte-derived macrophages (MΦ) infiltrate blood vessels to regulate several processes involved in vascular pathophysiology. However, little is known about the mediators involved. Macrophage polarization is crucial for a fast and efficient initial response (GM-MΦ) and a good resolution (M-MΦ) of the inflammatory process. The functional activity of polarized MΦ is exerted mainly through their secretome, which can target other cell types, including endothelial cells. Endoglin (CD105) is a cell surface receptor expressed by endothelial cells and MΦ that is markedly upregulated in inflammation and critically involved in angiogenesis. In addition, a soluble form of endoglin with anti-angiogenic activity has been described in inflammation-associated pathologies. The aim of this work was to identify components of the MΦ secretome involved in the shedding of soluble endoglin. We find that the GM-MΦ secretome contains metalloprotease 12 (MMP-12), a GM-MΦ specific marker that may account for the anti-angiogenic activity of the GM-MΦ secretome. Cell surface endoglin is present in both GM-MΦ and M-MΦ, but soluble endoglin is only detected in GM-MΦ culture supernatants. Moreover, MMP-12 is responsible for the shedding of soluble endoglin in vitro and in vivo by targeting membrane-bound endoglin in both MΦ and endothelial cells. These data demonstrate a direct correlation between GM-MΦ polarization, MMP-12, and soluble endoglin expression and function. By targeting endothelial cells, MMP-12 may represent a novel mediator involved in vascular homeostasis.
Dorjkhorloo G, Shiraishi T, Erkhem-Ochir B, Sohda M, Okami H, Yamaguchi A Sci Rep. 2024; 14(1):30735.
PMID: 39730445 PMC: 11680924. DOI: 10.1038/s41598-024-80489-w.
Ahmed N, Kummarapurugu A, Zheng S, Bulut G, Kang L, Batheja A Int J Mol Sci. 2024; 25(23).
PMID: 39684750 PMC: 11641719. DOI: 10.3390/ijms252313038.
Pereira da Fonseca A, Traidl S, Gutzmer R, Schaper-Gerhardt K, Werfel T, Mommert S Front Immunol. 2024; 15:1429009.
PMID: 39502691 PMC: 11536267. DOI: 10.3389/fimmu.2024.1429009.
van Vliet A, van den Hout M, Steenmans D, Duru A, Georgoudaki A, de Gruijl T Mol Ther Oncol. 2024; 32(4):200870.
PMID: 39346765 PMC: 11426129. DOI: 10.1016/j.omton.2024.200870.
Advances in Melanoma: From Genetic Insights to Therapeutic Innovations.
Valdez-Salazar F, Jimenez-Del Rio L, Padilla-Gutierrez J, Valle Y, Munoz-Valle J, Valdes-Alvarado E Biomedicines. 2024; 12(8).
PMID: 39200315 PMC: 11351162. DOI: 10.3390/biomedicines12081851.